Dell'Utri Chiara, Digesu G Alessandro, Bhide Alka, Khullar Vik
Department of Urogynaecology, St. Mary's Hospital, Cambridge Wing, Praed Street, London W1 1NY, United Kingdom.
Int Urogynecol J. 2012 Oct;23(10):1337-44. doi: 10.1007/s00192-012-1696-0. Epub 2012 Mar 13.
This is a systematic review of clinical data assessing the safety, efficacy and tolerability of fesoterodine in randomised control trials (RCTs) in the treatment of overactive bladder (OAB).
We performed a MEDLINE literature search of articles published between 2005 and 2010 regarding the efficacy and safety of fesoterodine. The US Food and Drug Administration Web site was also searched for RCTs.
Two studies demonstrated significant improvement of OAB symptoms with fesoterodine compared with placebo. Two phase III studies showed both doses of fesoterodine to be more effective than placebo for most symptoms. Another phase III trial confirmed the superiority of 8 mg fesoterodine compared with tolterodine ER 4 mg. Dry mouth was the commonest side effect.
Fesoterodine is effective for treating OAB symptoms. Its once-daily dosing regime and the flexibility to increase the dose are appealing factors.
这是一项对临床数据的系统评价，该数据评估了非索罗定在治疗膀胱过度活动症（OAB）的随机对照试验（RCT）中的安全性、有效性和耐受性。
我们对2005年至2010年间发表的有关非索罗定有效性和安全性的文章进行了MEDLINE文献检索。还在美国食品药品监督管理局网站上搜索了随机对照试验。
两项研究表明，与安慰剂相比，非索罗定可显著改善膀胱过度活动症症状。两项III期研究表明，两种剂量的非索罗定在大多数症状方面均比安慰剂更有效。另一项III期试验证实，8毫克非索罗定比4毫克缓释托特罗定更具优势。口干是最常见的副作用。
非索罗定对治疗膀胱过度活动症症状有效。其每日一次的给药方案以及增加剂量的灵活性是吸引人的因素。
